A. Flaxman

发表

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

A. Lawrie, A. Hill, S. Gilbert, 2019, Vaccines.

Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis

A. Chalmers, A. Ward, F. Latif, 2010, The Biochemical journal.

Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease.

D. Wyllie, A. Milicic, A. Flaxman, 2019, Vaccine.

A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector

R. Hewson, E. Wright, H. Sharpe, 2020, Vaccines.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

A. Pollard, P. Aley, M. Voysey, 2022, eBioMedicine.

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Nguyen H. Tran, A. Lawrie, A. Hill, 2020, The Lancet. Infectious diseases.

Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open- labelled, first-in-human, dose-escalation trial

Nguyen H. Tran, A. Lawrie, A. Hill, 2020 .

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

A. Pollard, P. Aley, L. Godfrey, 2022, The Lancet.

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

P. Klenerman, T. Wrin, C. Petropoulos, 2021, Nature Communications.

Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination.

D. Wyllie, A. Flaxman, C. Rollier, 2019, Vaccine.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

T. Lambe, M. Baker, K. Ewer, 2022, eBioMedicine.

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

J. Knight, V. Libri, A. Mentzer, 2022, Nature Medicine.

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

D. Stuart, P. Klenerman, J. Knight, 2021, Cell.

Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity

D. Stuart, P. Klenerman, J. Knight, 2021, Social Science Research Network.

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)

Ly-Mee Yu, A. Lawrie, M. Shanyinde, 2021, Vaccines.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

V. Munster, E. de Wit, N. van Doremalen, 2020, Nature.

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

O. Traoré, H. Tinto, H. Sorgho, 2021, The Lancet.

Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria

Dimitrios Voukantsis, K. Ewer, D. Bellamy, 2022, Frontiers in Immunology.

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

D. Stuart, P. Klenerman, J. Knight, 2021, Cell.

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

S. Madhi, D. Stuart, P. Klenerman, 2022, Cell.

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination

P. Klenerman, A. Pollard, N. Provine, 2022, JCI Insight.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

P. Klenerman, M. Pirmohamed, A. Sette, 2020, Nature Communications.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

V. Munster, E. de Wit, N. van Doremalen, 2020, bioRxiv.

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Young Chan Kim, A. Lawrie, A. Hill, 2021, Nature Communications.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

D. Bonsall, V. Libri, J. Vekemans, 2021 .

Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man

K. Ewer, A. Flaxman, 2018, Vaccines.

Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation

Konrad U. Förstner, Daniel J. Wilson, Christian W. Remmele, 2016, Proceedings of the National Academy of Sciences.

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

S. Madhi, P. Klenerman, G. Screaton, 2021, bioRxiv.

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

S. Madhi, D. Stuart, P. Klenerman, 2021, Cell.

Antibody evasion by the P.1 strain of SARS-CoV-2

D. Stuart, P. Klenerman, J. Knight, 2021, Cell.

Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2

D. Stuart, P. Klenerman, J. Knight, 2021, bioRxiv.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, M. Wand, 2021, Nature Medicine.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

G. Screaton, P. Aley, B. Angus, 2021, SSRN Electronic Journal.

Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

V. Munster, E. de Wit, N. van Doremalen, 2021, Nature.

Development of persistent gastrointestinal S. aureus carriage in mice

D. Wyllie, A. Milicic, A. Flaxman, 2017, Scientific Reports.

Population variation in anti-S. aureus IgG isotypes influences surface protein A mediated immune subversion.

M. O’Shea, D. Wyllie, J. Fallowfield, 2016, Vaccine.

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

V. Munster, E. de Wit, N. van Doremalen, 2020, Nature.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

A. Pollard, P. Aley, M. Voysey, 2023, Clinical and experimental immunology.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, P. Klenerman, T. Wrin, 2021, Nature Medicine.

High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso

O. Traoré, H. Tinto, H. Sorgho, 2021 .

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax

M. Bachmann, G. Cabral-Miranda, A. Flaxman, 2017, Vaccines.

Risk factors for dermatitis in submariners during a submerged patrol: an observational cohort study

M. O’Shea, D. Wyllie, J. Fallowfield, 2016, BMJ Open.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

A. Pollard, P. Aley, B. Angus, 2020, Lancet.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

A. Pollard, P. Aley, B. Angus, 2020, Lancet.